Rlam-1 (Alprazolam Tablets I.P. 1 mg)

Rlam-1 (Alprazolam Tablets I.P. 1 mg) – Clinical Information, Uses, and Safety Profile

Overview

Rlam-1 (Alprazolam Tablets I.P. 1 mg), manufactured by Aran Pharmaceuticals, is a prescription medicine belonging to the benzodiazepine class of anxiolytics.
Each tablet contains 1 mg of Alprazolam, formulated to provide effective short-term management of anxiety disorders, panic disorder, and anxiety-related insomnia.

Alprazolam works by enhancing the action of gamma-aminobutyric acid (GABA)—the brain’s chief inhibitory neurotransmitter—producing a calming effect that helps reduce anxiety and tension.
When used as directed by a qualified healthcare professional, Rlam-1 can help patients regain mental balance, relieve restlessness, and improve sleep quality.

Pharmacological Classification

Category	Description
Therapeutic class	Anxiolytic / Sedative
Pharmacological class	Benzodiazepine derivative
Active ingredient	Alprazolam I.P. 1 mg
Dosage form	Oral tablet
Manufacturer	Aran Pharmaceuticals
Packaging	8 × 5 × 15 tablets
Regulatory status	Prescription medicine (Schedule H / Controlled Substance in many regions)

Mechanism of Action

Alprazolam acts as a positive allosteric modulator of the GABA-A receptor complex.
By binding to a specific site on this receptor, it increases the affinity of GABA for its binding site, resulting in enhanced chloride-ion influx and subsequent neuronal hyperpolarization.
This neurochemical change decreases excessive neuronal firing within the limbic system and cortical pathways—areas responsible for regulating fear, anxiety, and emotional behavior.

The outcome is a measurable reduction in:

• Somatic symptoms of anxiety (palpitations, tremors, sweating).
• Cognitive symptoms (excessive worry, inability to relax).
• Sleep disturbances caused by hyperarousal.

Therapeutic Indications

Rlam-1 (Alprazolam Tablets I.P. 1 mg) is indicated for the short-term treatment of:

1. Generalized Anxiety Disorder (GAD)
   – Characterized by persistent, excessive anxiety and worry that interferes with daily functioning.
2. Panic Disorder (with or without agoraphobia)
   – Recurrent panic attacks accompanied by intense fear or physiological distress.
3. Anxiety-related Insomnia
   – Difficulty falling or staying asleep due to heightened nervous tension.
4. Anxiety Associated with Depression
   – Adjunctive therapy in depressive illness when anxiety is a prominent feature.

Key Clinical Features

• Rapid Onset of Action – Produces noticeable calming effects typically within 30 to 60 minutes.
• Short Elimination Half-life – Reduces risk of prolonged sedation when taken as prescribed.
• Clinically Proven Efficacy – Extensive evidence supports Alprazolam’s role in controlling anxiety and panic symptoms.
• Improved Sleep Quality – Restores normal sleep architecture disrupted by anxiety.
• Convenient Dosing – 1 mg tablets allow flexible titration and physician-guided dose adjustment.
• Quality Manufacturing – Produced under strict Indian Pharmacopoeia (I.P.) and Good Manufacturing Practice (GMP) standards by Aran Pharmaceuticals.

Pharmacokinetics

Parameter	Description
Absorption	Rapidly absorbed from the gastrointestinal tract; peak plasma concentrations within 1–2 hours.
Bioavailability	Approximately 80–90 %.
Protein binding	~80 %.
Metabolism	Primarily hepatic via CYP3A4 enzyme pathways.
Elimination half-life	11–15 hours (varies with age and health).
Excretion	Renal, primarily as metabolites.

Dosage and Administration

Important: Dosage must be individualized and prescribed only by a qualified healthcare professional.

Typical adult dosing:

• Initial dose for anxiety: 0.25 mg to 0.5 mg, two or three times daily.
• Dose may be gradually increased, not exceeding 4 mg per day in divided doses for most patients.

For panic disorder:

• Initial: 0.5 mg three times daily; titrate based on clinical response.

Administration guidelines:

• Tablets are taken orally, with or without food.
• Swallow whole with water; do not crush or chew.
• Treatment duration should be as short as possible, with periodic reassessment.
• Gradual tapering is essential to avoid withdrawal symptoms upon discontinuation.

Target Audience

• Adults (18 years and older) experiencing clinically diagnosed anxiety or panic disorders.
• Individuals under psychiatric or general-medical supervision requiring short-term pharmacologic support.
• Healthcare professionals managing patients with acute stress reactions or insomnia linked to anxiety.

Clinical Benefits

When used correctly under medical supervision, Rlam-1 (Alprazolam Tablets I.P. 1 mg) can:

1. Reduce Excessive Anxiety: Calms hyperactive neural pathways responsible for fear and worry.
2. Restore Emotional Stability: Supports balanced mood and improved coping ability.
3. Alleviate Panic Symptoms: Controls palpitations, breathlessness, and dizziness associated with panic attacks.
4. Improve Sleep Patterns: Promotes relaxation that leads to restorative sleep.
5. Enhance Daily Functioning: Enables patients to focus on work, relationships, and daily activities without overwhelming tension.

Contraindications

• Hypersensitivity to Alprazolam or other benzodiazepines.
• Severe respiratory insufficiency or sleep apnea.
• Acute narrow-angle glaucoma.
• Myasthenia gravis (relative contraindication).
• Pregnancy and lactation (risk of fetal and neonatal sedation).

Warnings and Precautions

1. Dependence and Withdrawal:
   Prolonged use may lead to physical or psychological dependence. Taper dosage gradually to discontinue safely.
2. Sedation and Cognitive Impairment:
   May reduce alertness; avoid driving or operating machinery after ingestion.
3. Elderly Patients:
   Increased sensitivity to sedative effects; lower starting doses recommended.
4. Interactions:
   Use caution with CNS depressants (opioids, alcohol, antihistamines) which may enhance sedation.
5. Mental Health Monitoring:
   Patients with depression should be observed closely; Alprazolam does not treat underlying depressive disorders.
6. Liver or Kidney Impairment:
   Dose adjustments may be necessary.

Adverse Reactions

Common	Less Common	Rare but Serious
Drowsiness, fatigue	Confusion, blurred vision	Dependence, withdrawal seizures
Lightheadedness	Irritability, mood swings	Respiratory depression (high doses)
Dry mouth, nausea	Decreased coordination	Paradoxical agitation in elderly

Side-effects often diminish with continued use or dose adjustment.

Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increase Alprazolam levels.
• CYP3A4 inducers (e.g., rifampicin) may reduce therapeutic effect.
• Opioids and alcohol enhance CNS depression.
• Antidepressants or antipsychotics may increase sedation or alter response.

Always disclose all medications and supplements to the prescriber.

Overdose Information

Symptoms: Profound drowsiness, confusion, impaired coordination, hypotension, respiratory depression, or coma.
Management: Supportive care and airway protection. Flumazenil, a benzodiazepine antagonist, may be used under controlled conditions by medical professionals.

Use in Specific Populations

• Pregnancy: Category D (positive evidence of risk).
• Lactation: Excreted in breast milk; may cause sedation in infants.
• Pediatrics: Not recommended under 18 years unless specifically indicated.
• Geriatrics: Start with the lowest possible dose (0.25 mg twice daily).
• Hepatic impairment: Use reduced dosage; monitor for accumulation.

Storage and Handling

• Store below 30 °C, away from direct light and moisture.
• Keep out of reach of children.
• Do not use after the expiry date printed on the pack.
• Dispose of unused tablets according to local pharmaceutical-waste guidelines.

Patient Counseling Points

Healthcare professionals should educate patients on:

1. Proper Dosage and Duration – Follow the prescription exactly.
2. Avoiding Alcohol and Sedatives – Increases sedation risk.
3. Gradual Withdrawal – Prevents rebound anxiety or seizures.
4. Safe Storage – Prevent accidental ingestion, especially by children.
5. Signs of Dependence – Report craving, dose escalation, or withdrawal effects.

Problem Addressed

Anxiety and panic disorders represent some of the most prevalent mental-health conditions globally. Persistent worry, nervous tension, insomnia, and physical restlessness can significantly reduce quality of life.

For patients whose symptoms cannot be managed through behavioral therapy alone, short-term pharmacological support may be necessary.
Rlam-1 (Alprazolam Tablets I.P. 1 mg) provides this relief by modulating the brain’s natural calming system, helping stabilize emotional responses and reducing the physiological symptoms of anxiety.

Desired Outcomes and Benefits

• Rapid Symptom Relief: Fast absorption ensures early onset of action.
• Mental and Physical Calmness: Promotes relaxation of both mind and body.
• Restorative Sleep: Reduces nighttime anxiety for better rest.
• Improved Daily Productivity: Minimizes distraction caused by fear or nervousness.
• Enhanced Quality of Life: Allows individuals to regain confidence and social functionality.

Search Optimization Notes (for backend use)

Primary SEO Keywords:
Alprazolam 1 mg tablets, Rlam-1, Alprazolam I.P. 1 mg information, benzodiazepine anxiolytic, panic disorder treatment guide, anxiety relief medication, Alprazolam precautions, Aran Pharmaceuticals Alprazolam, Alprazolam side effects, safe use of benzodiazepines.

Suggested Meta Title:
“Rlam-1 (Alprazolam Tablets I.P. 1 mg) – Medical Information, Uses, and Safety”

Suggested Meta Description:
“Learn about Rlam-1 (Alprazolam 1 mg) tablets, a prescription benzodiazepine used under medical supervision for anxiety and panic disorders. Includes dosage, precautions, side-effects, and safe-use information.”

Legal and Regulatory Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice or promotional material.
Alprazolam is a prescription-only benzodiazepine that must be used strictly under the guidance of a licensed physician.
Regulations regarding controlled substances vary by country; pharmacies and practitioners must comply with applicable national laws.
Patients should never purchase or use Alprazolam without a valid prescription and professional supervision.

 

Conclusion

Rlam-1 (Alprazolam Tablets I.P. 1 mg) is a medically recognized therapy for short-term management of anxiety and panic disorders.
When used responsibly, it offers reliable, evidence-based symptom relief—helping patients regain calmness, confidence, and sleep quality.
Because of its potential for dependence, however, treatment must always be personalized, closely supervised, and limited to the prescribed duration.